Emerging within the UK, retatrutide, a novel compound , is generating considerable interest within the scientific community regarding its potential for body regulation. This dual GIP and GLP-1 agent agonist seems to offer a significant benefit over existing therapies, showing positive results in preliminary clinical trials . Researchers believe its